Robert Gagnon

3.6k citations

49 papers · 2.6k indexed · 1 hit paper · h-index 23

Pulmonary and Respiratory Medicine top 2%
Oncology top 5%
Molecular Biology top 10%
Cancer Research top 5%
Physiology top 10%

Co-authors: David M. Mannino Thomas L. Petty Eva Lydick Frank C. Barone Raymond F. White Tianli Yue Giora Feuerstein Xinkang Wang
Topics: HER2/EGFR in Cancer Research (12 papers)Monoclonal and Polyclonal Antibodies Research (8 papers)Renal cell carcinoma treatment (7 papers)
Cited by: Pulmonary and Respiratory Medicine Oncology Cancer Research
Journals: Journal of Clinical Oncology PLoS ONE Cancer
Partner nations: United States United Kingdom Italy

In The Last Decade

Robert Gagnon

49 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Obstructive Lung Disease and Low Lung Function in Adults in the United States

2000 564 citations David M. Mannino, Robert Gagnon et al. Archives of Internal Medicine profile →

Peers

Countries citing papers authored by Robert Gagnon

Since Specialization

Citations

This map shows the geographic impact of Robert Gagnon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Gagnon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Gagnon more than expected).

Fields of papers citing papers by Robert Gagnon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Gagnon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Gagnon. The network helps show where Robert Gagnon may publish in the future.

Co-authorship network of co-authors of Robert Gagnon

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Gagnon. A scholar is included among the top collaborators of Robert Gagnon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Gagnon. Robert Gagnon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors 2021 ·The Oncologist ·Hui Gan,Michael Millward,Mathilde Jalving,Ignacio Garrido‐Laguna,Jason D. Lickliter,Jan H.M. Schellens,Martijn P. Lolkema,(unknown),Bruce A. Hug,Lihua Tang,Robin O'Connor‐Semmes,Robert Gagnon,Catherine Ellis,Gopinath Ganji,Christopher Matheny,Alexander Drilon	27
2	11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study 2020 ·Annals of Oncology ·Eric Angevin,Stefanie L. Groenland,Todd M. Bauer,Danny Rischin,(unknown),(unknown),José Trigo,Michael Chisamore,Jafar Sadik Shaik,Fabio Rigat,(unknown),(unknown),Robert Gagnon,(unknown),David C. Turner,Sapna Yadavilli,Marc Ballas,Axel Hoos,Michele Maio	2
3	Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis 2018 ·CHEST Journal ·Scott M. Palmer,Laurie D. Snyder,Jamie L. Todd,Benjamin P. Soule,Rose Christian,Kevin J. Anstrom,Yi Luo,Robert Gagnon,Glenn D. Rosen	138
4	Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents 2017 ·Neuromuscular Disorders ·Alan S. Robertson,Mark J. Majchrzak,(unknown),Robert Gagnon,Nino Devidze,Glen B. Banks,Sean C. Little,(unknown),Denise I. Bounous,(unknown),Leslie K. Jacobsen,Linda J. Bristow,Michael K. Ahlijanian,Stephen A. Stimpson	31
5	A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma 2016 ·Clinical Cancer Research ·Thomas Yau,Riccardo Lencioni,Wattana Sukeepaisarnjaroen,Yee Chao,Chia-Jui Yen,(unknown),Pei‐Jer Chen,(unknown),(unknown),Donna S. Cox,Robert Gagnon,Yuan Liu,(unknown),Diptee Kulkarni,Howard Kallender,Lone H. Ottesen,Ronnie T.P. Poon,Donald P. Bottaro	58
6	Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials 2015 ·Clinical Cancer Research ·Ademi Santiago-Walker,Robert Gagnon,Jolly Mazumdar,Michelle Casey,Georgina V. Long,Dirk Schadendorf,Keith T. Flaherty,Richard Kefford,Axel Hauschild,Patrick Hwu,Patricia Haney,Anne O’Hagan,Jennifer Carver,Vicki Goodman,Jeffrey J. Legos,Anne‐Marie Martin	158
7	Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial 2014 ·Clinical Cancer Research ·Toni K. Choueiri,David J. Figueroa,André P. Fay,Sabina Signoretti,Yuan Liu,Robert Gagnon,Keith C. Deen,Christopher Carpenter,(unknown),Thai H. Ho,Lini Pandite,Paul de Souza,Thomas Powles,Robert J. Motzer	187
8	The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma 2013 ·Clinical Cancer Research ·Toni K. Choueiri,André P. Fay,Robert Gagnon,Ying Lin,Brittany Bahamón,Victoria E. Brown,Jonathan E. Rosenberg,Thomas E. Hutson,Katherine L. Baker-Neblett,Christopher L. Carpenter,Yuan Liu,Lini Pandite,Sabina Signoretti	73
9	Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study 2013 ·Breast Cancer ·Hiroji Iwata,Hirofumi Fujii,Norikazu Masuda,Hirofumi Mukai,(unknown),(unknown),Catherine Ellis,Robert Gagnon,Seigo Nakamura	7
10	Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer 2013 ·PLoS ONE ·Manish A. Shah,Zev A. Wainberg,Daniel V.T. Catenacci,Howard S. Höchster,James M. Ford,Pamela L. Kunz,Fa-Chyi Lee,Howard Kallender,Franco Cecchi,Daniel C. Rabe,Harold Keer,Anne‐Marie Martin,Yuan Liu,Robert Gagnon,Peter L. Bonate,Li Liu,Tona M. Gilmer,Donald P. Bottaro	182
11	Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression‐free survival in patients with HER2‐positive metastatic breast cancer receiving lapatinib monotherapy 2011 ·Cancer ·Allan Lipton,Kim Leitzel,Suhail M. Ali,Walter P. Carney,(unknown),Klaudia Steplewski,Ron E. Westlund,Robert Gagnon,Anne‐Marie Martin,J. Maltzman	19
12	Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor 2010 ·Clinical Cancer Research ·Maurizio Scaltriti,Sarat Chandarlapaty,Ludmila Prudkin,Claudia Aura,José Jiménez,(unknown),(unknown),Marta Guzmán,Josep Lluís Parra,Catherine Ellis,Robert Gagnon,María Koehler,Henry Gómez,Charles E. Geyer,David Cameron,Joaquı́n Arribas,Neal Rosen,José Baselga	114
13	Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies 2009 ·British Journal of Cancer ·Masakazu Toi,Hiroji Iwata,Yasuhiro Fujiwara,Yoshiaki Ito,Shôji Nakamura,Yutaka Tokuda,Tetsuya Taguchi,Yoshiaki Rai,K. Aogi,(unknown),Junichiro Watanabe,(unknown),(unknown),Catherine Ellis,Robert Gagnon,Kathleen Allen,Yosuke Sasaki,Shigemitsu Takashima	68
14	Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients 2009 ·Molecular Cancer Therapeutics ·Franco Cecchi,(unknown),Robert Gagnon,Howard Kallender,Daniel C. Rabe,Manish A. Shah,Anne‐Marie Martin,Donald P. Bottaro	2
15	HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer 2008 ·Clinical Cancer Research ·Michael F. Press,Richard S. Finn,David Cameron,Angelo Di Leo,Charles E. Geyer,Ivonne Villalobos,Angela Santiago,Roberta Guzman,Armen Yuri Gasparyan,Yanling Ma,K. D. Danenberg,Anne Marie Martin,Lisa Williams,Cristina Oliva,Steven Stein,Robert Gagnon,Michael Arbushites,María Koehler	134
16	Physician‐rated patient preference and patient‐ and partner‐rated preference for tadalafil or sildenafil citrate: results from the Canadian ‘Treatment of Erectile Dysfunction’ observational study 2006 ·British Journal of Urology ·Lee Jc,Peter Pommerville,Gerald Brock,Robert Gagnon,(unknown),(unknown),Melanie Chan,John Chan,R. A. Dickson	16
17	Modification of the Fc Region of a Primatized IgG Antibody to Human CD4 Retains Its Ability to Modulate CD4 Receptors but Does Not Deplete CD4+ T Cells in Chimpanzees 2001 ·Clinical Immunology ·Roland Newman,Kandasamy Hariharan,Mitchell E. Reff,(unknown),Gary R. Braslawsky,(unknown),Nabil Hanna,Peter J. Bugelski,Michael Brigham‐Burke,Carl Crysler,Robert Gagnon,(unknown),Michael L. Doyle,Preston Hensley,Manjula Reddy,Raymond W. Sweet,Alemseged Truneh	45
18	Obstructive Lung Disease and Low Lung Function in Adults in the United Statesbreakdown → 2000 ·Archives of Internal Medicine ·David M. Mannino,Robert Gagnon,Thomas L. Petty,Eva Lydick	564
19	Estimation of Confidence Intervals for Area Under the Curve from Destructively Obtained Pharmacokinetic Data 1998 ·Journal of Pharmacokinetics and Biopharmaceutics ·Robert Gagnon,(unknown)	84
20	Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730) 1993 ·European Journal of Pharmacology ·Edward F. Smith,D.E. Griswold,John Egan,Leonard M. Hillegass,Richard Smith,Martin Hibbs,Robert Gagnon	38

About Robert Gagnon

Robert Gagnon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 49 papers that have together received 2.6k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (12 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Renal cell carcinoma treatment (7 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.1k citations), Oncology (896 citations) and Cancer Research (414 citations). Robert Gagnon has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include David M. Mannino, Thomas L. Petty, Eva Lydick, Frank C. Barone, Raymond F. White, Tianli Yue, Giora Feuerstein, Xinkang Wang, Sergei Leonov and Tona M. Gilmer. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact